The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
Open accessAbstract
IN BRIEF Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety of reasons, treatment is often not intensified in a timely manner. The combined use of basal insulin and a glucagon-like peptide-1 receptor agonist is recognized to provide a complementary approach to the treatment of type 2 diabetes. This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone. We consider the benefits and limitations of these medications based on data from randomized clinical trials and discuss how they may address barriers to treatment intensification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The combination of basal insulin with GLP-1 RA results in greater glycemic lowering ef fi cacy than the monocomponents, with less weight gain and lower rates of hypoglycemia than with intensi fi ed insulin regimens, and better gastrointestinal tolerability than with GLP-1 RA alone (214,215).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“The importance of good glycemic control has been well established and has been shown to reduce the risk of long-term diabetes complications such as retinopathy and nephropathy (3,4).”
Background10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The importance of good glycemic control has been well established and has been shown to reduce the risk of long-term diabetes complications such as retinopathy and nephropathy (3,4).”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“Insulin is recognized as the most effective glucose-lowering therapy (21,22), with basal insulin predominately lowering A1C as a result of its action on fasting plasma glucose (FPG) (23).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“No CVOTs are currently planned for the coformulations because the cardiovascular safety of their monocomponents has been investigated extensively in their respective CVOTs (42,43,46,51).”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 2×
“No CVOTs are currently planned for the coformulations because the cardiovascular safety of their monocomponents has been investigated extensively in their respective CVOTs (42,43,46,51).”
Standards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,465
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Research works printed but not linked: 3
- Berard, 2016, Drivers of and barriers to optimal basal insulin (BI) titration: results of a quantitative survey (Abstract), Diabetes, 65, 972-P
- Peyrot, 2016, Reasons for different patterns of basal insulin persistence after initiation among people with type 2 diabetes mellitus (T2DM) (Abstract), Diabetes, 65, 787-P
- Billings, 2017, Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal-bolus (BB) therapy in patients with type 2 diabetes (T2D): DUAL VII trial (Abstract 136-OR), Diabetes, 66, A36
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationAroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
Self-citationWatada, H., Kaneko, S., Komatsu, M., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Nakamura, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13859 · Cited by 37
Zhang, H., Chu, Y., Zheng, H., Wang, J., Song, B., & Sun, Y. (2020) · Aging · doi:10.18632/aging.202162 · Cited by 26
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.025 · Cited by 11
Cannon, A. J., Bargiota, Α., Billings, L. K., Hunt, B., Leiter, L. A., Malkin, S. J. P., Mocarski, M., Ranthe, M. F., Schiffman, A. B., & Doshi, A. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.19035 · Cited by 7
Self-citationGiorgino, F., Guja, C., Aydın, H., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111604 · Cited by 2
Davidson, J. A., Desouza, C. V., Fonseca, V. A., Frías, J. P., Gaal, L. V., Giorgino, F., Chao, J., DEX, T. A., Roberts, M., Saremi, A., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.14094 · Cited by 2
Kandalam, S., Benamar, M., Reun, C. L., Rengger, L., Gupta, P., & Nair, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01847-7 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Self-citationThere Are Great New Medications Out There—Why Aren’t We Using Them?
Brunton, S. (2018) · Clinical Diabetes · doi:10.2337/cd18-0011
Modern insulin treatment for type 2 diabetes
Grønlund, E., Lund, L., Vilsbøll, T., & Hædersdal, S. (2024) · Ugeskrift for Læger · doi:10.61409/v03240172
Metadata
- Authors
- Aroda, V. R., Arulandu, J. R., & Cannon, A. J.
- Affiliations
- MedStar Health Research Institute (US)
- Indiana University Health (US)
- Endocrine Metabolic Associates and ARIA Healthcare, Philadelphia, PA
- Corresponding author
- Aroda, Vanita R.
- Venue
- Clinical Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-04-01
- Volume
- 36
- Issue
- 2
- Pages
- 138-147
- ISSN
- 0891-8929 (ISSN-L)
- 1945-4953
- PMC
- PMC5898167
- OpenAlex
- W2793531770
- Cited by
- 13
- References
- 46
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2020: 1 · 2019: 3 · 2018: 2
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Novo Nordisk
- National Institutes of Health (UL1TR001409)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, IDegLira, basal insulin, GLP-1 receptor agonists, glycemic control, treatment intensification, drug safety and efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.